IL252863A0 - Compounds 5,4,3,2-tetrahydropyridine-6-amine and 4,3-dihydro-h2-pyrrole-5-amine beta-secretase inhibitors - Google Patents

Compounds 5,4,3,2-tetrahydropyridine-6-amine and 4,3-dihydro-h2-pyrrole-5-amine beta-secretase inhibitors

Info

Publication number
IL252863A0
IL252863A0 IL252863A IL25286317A IL252863A0 IL 252863 A0 IL252863 A0 IL 252863A0 IL 252863 A IL252863 A IL 252863A IL 25286317 A IL25286317 A IL 25286317A IL 252863 A0 IL252863 A0 IL 252863A0
Authority
IL
Israel
Prior art keywords
amine
tetrahydropyridin
secretase
pyrrol
dihydro
Prior art date
Application number
IL252863A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of IL252863A0 publication Critical patent/IL252863A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL252863A 2014-12-18 2017-06-13 Compounds 5,4,3,2-tetrahydropyridine-6-amine and 4,3-dihydro-h2-pyrrole-5-amine beta-secretase inhibitors IL252863A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14198977 2014-12-18
EP15164704 2015-04-22
PCT/EP2015/079981 WO2016096979A1 (en) 2014-12-18 2015-12-16 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase

Publications (1)

Publication Number Publication Date
IL252863A0 true IL252863A0 (en) 2017-08-31

Family

ID=55070992

Family Applications (1)

Application Number Title Priority Date Filing Date
IL252863A IL252863A0 (en) 2014-12-18 2017-06-13 Compounds 5,4,3,2-tetrahydropyridine-6-amine and 4,3-dihydro-h2-pyrrole-5-amine beta-secretase inhibitors

Country Status (13)

Country Link
US (1) US10106524B2 (cg-RX-API-DMAC7.html)
EP (1) EP3233834B1 (cg-RX-API-DMAC7.html)
JP (1) JP2017538753A (cg-RX-API-DMAC7.html)
KR (1) KR20170095881A (cg-RX-API-DMAC7.html)
CN (1) CN107108582B (cg-RX-API-DMAC7.html)
AU (1) AU2015367594C1 (cg-RX-API-DMAC7.html)
CA (1) CA2967164A1 (cg-RX-API-DMAC7.html)
EA (1) EA031041B1 (cg-RX-API-DMAC7.html)
ES (1) ES2768823T3 (cg-RX-API-DMAC7.html)
IL (1) IL252863A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017008083A (cg-RX-API-DMAC7.html)
WO (1) WO2016096979A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201704116B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2580200B1 (en) 2010-06-09 2016-09-14 Janssen Pharmaceutica, N.V. 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
EP2655376B1 (en) 2010-12-22 2017-08-23 Janssen Pharmaceutica NV 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
CN103415521B (zh) 2011-03-09 2016-01-06 詹森药业有限公司 用作β分泌酶(BACE)抑制剂的3,4-二氢-吡咯并[1,2-a]吡嗪-1-基胺衍生物
MX368326B (es) 2013-06-12 2019-09-27 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5-a]pirazin-3(2h )-ona como inhibidores de beta-secretasa (bace).
ES2721073T3 (es) 2013-06-12 2019-07-26 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-6,7-dihidro[1,2,3]triazolo[1,5 a]pirazina como inhibidores de beta-secretasa (BACE)
US10106524B2 (en) 2014-12-18 2018-10-23 Janssen Pharmaceutica Nv 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase
MA46698A (fr) * 2016-11-04 2021-04-07 Janssen Pharmaceutica Nv Composés de 4,4 a, 5,7-têtrahydro -3 h-furo [3,4-b]pyridinyl
CN116059192B (zh) 2019-11-13 2024-10-29 润佳(苏州)医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
CN113549007B (zh) * 2021-07-23 2023-07-18 清华大学 一种哌啶乙酸酯类化合物的制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188389A (en) 1978-11-03 1980-02-12 Ayerst Mckenna & Harrison, Inc. 1,2,3,4-Tetrahydropyrrolo(1,2-A)pyrazines
TW224974B (cg-RX-API-DMAC7.html) 1991-07-02 1994-06-11 Hoffmann La Roche
CA2293408A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
IL164703A0 (en) 2002-04-19 2005-12-18 Cellular Genomics Inc ImidazoÄ1,2-AÜpyrazin-8-ylamines method of making and method of use thereof
MXPA05003120A (es) 2002-09-23 2005-06-22 Schering Corp Imidazopirazinas como inhibidores de cinasa dependientes de ciclinas.
MXPA05006568A (es) 2002-12-20 2005-09-22 Pharmacia Corp Compuestos de pirazol aciclico para la inhibicion de proteina cinasa-2 activada por proteina cinasa activada por mitogenos.
US7402592B2 (en) 2003-10-15 2008-07-22 Targacept, Inc. Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders
WO2005108391A1 (en) 2004-04-22 2005-11-17 Eli Lilly And Company Amides as bace inhibitors
AU2005264915A1 (en) 2004-06-16 2006-01-26 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
TW200624426A (en) 2004-09-21 2006-07-16 Lilly Co Eli BACE inhibitors
RU2007126570A (ru) 2005-01-14 2009-02-20 Вайет (Us) Аминоимидазолоны, применяемые для ингибирования бета-секретазы
US20070005404A1 (en) 2005-06-09 2007-01-04 Drive Diagnostics Ltd. System and method for providing driving insurance
MX2007016183A (es) 2005-06-14 2008-03-10 Schering Corp Preparacion y uso de compuestos como inhibidores de proteasas.
EP1896448A1 (en) 2005-06-30 2008-03-12 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
KR101052122B1 (ko) 2005-10-25 2011-07-26 시오노기세야쿠 가부시키가이샤 아미노디히드로티아진 유도체
TW200804290A (en) 2005-11-15 2008-01-16 Astrazeneca Ab Compounds and uses thereof
US20090099217A1 (en) 2006-04-05 2009-04-16 Astex Therapeutics Ltd. 2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies
US20080051420A1 (en) 2006-06-14 2008-02-28 Astrazeneca Ab New Compounds 317
MX2009011498A (es) 2007-04-24 2009-11-10 Shionogi & Co Derivados de aminodihidrotiazina sustituida con un grupo ciclico.
TW200902499A (en) 2007-05-15 2009-01-16 Astrazeneca Ab New compounds
WO2009058300A1 (en) 2007-10-30 2009-05-07 Arena Pharmaceuticals, Inc. Biphenyl derivatives as modulators of the histamine-h3 receptor useful for the treatment of disorders related thereto
RU2497821C2 (ru) 2008-01-28 2013-11-10 Янссен Фармацевтика Нв ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННОГО-ТИО (ИЛИ -ОКСО-)-2-АМИНО-ХИНОЛИНА, ПРИМЕНЯЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКРЕТАЗЫ (BACE)
CA2714414A1 (en) 2008-02-13 2009-08-20 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
TWI431004B (zh) 2008-05-02 2014-03-21 Lilly Co Eli Bace抑制劑
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
WO2011002409A1 (en) 2009-07-02 2011-01-06 Astrazeneca Ab 5h-pyrrolo[3,4-£>]pyrazin-7-amine derivatives inhibitors of beta-secretase
AR077277A1 (es) 2009-07-09 2011-08-17 Lilly Co Eli Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
UY32799A (es) 2009-07-24 2011-02-28 Novartis Ag Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
US8188079B2 (en) 2009-08-19 2012-05-29 Hoffman-La Roche Inc. 3-amino-5-phenyl-5,6-dihydro-2H-[1,4]oxazines
US20120238557A1 (en) 2009-11-13 2012-09-20 Shionogi & Co., Ltd. Aminothiazine or aminooxazine derivative having amino linker
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
US20120258961A1 (en) * 2009-12-24 2012-10-11 Shionogi & Co., Ltd. 4-amino-1,3-thiazine or oxazine derivative
WO2011080176A1 (en) 2009-12-31 2011-07-07 Novartis Ag Pyrazine derivatives and their use in the treatment of neurological disorders
PH12012502379A1 (en) 2010-06-09 2013-02-18 Janssen Pharmaceutica Nv 5-amino-3,6-dihydro-1h-pyrazin-2-one derivatives useful as inhibitors of beta-secretase (bace)
EP2580200B1 (en) 2010-06-09 2016-09-14 Janssen Pharmaceutica, N.V. 5,6-dihydro-2h-[1,4]oxazin-3-yl-amine derivatives useful as inhibitors of beta-secretase (bace)
EA201291413A1 (ru) 2010-06-28 2013-05-30 Янссен Фармацевтика Нв Производные 3-амино-5,6-дигидро-1h-пиразин-2-она, применимые для лечения болезни альцгеймера и других форм деменции
JP5797756B2 (ja) 2010-09-22 2015-10-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap ベータ−セクレターゼ(BACE)の阻害剤として有用な4,7−ジヒドロ−ピラゾロ[1,5−a]ピラジン−6−イルアミン誘導体
WO2012057247A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
EP2655376B1 (en) 2010-12-22 2017-08-23 Janssen Pharmaceutica NV 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE)
EA201391029A1 (ru) 2011-01-12 2014-01-30 Новартис Аг Производные оксазина и их применение при лечении неврологических нарушений
MX2013008192A (es) 2011-01-13 2013-12-16 Novartis Ag Inhibidores de bace-2 para tratamiento de transtornos metabolicos.
JP2012147763A (ja) 2011-01-17 2012-08-09 Toshitaka Kobayashi 乾物穿孔具
US9242943B2 (en) 2011-01-18 2016-01-26 Siena Biotech S.P.A. 1,4 oxazines as BACE1 and/or BACE2 inhibitors
WO2012117027A1 (en) 2011-03-01 2012-09-07 Janssen Pharmaceutica Nv 6,7-dihydro-pyrazolo[1,5-a]pyrazin-4-ylamine derivatives useful as inhibitors of beta-secretase (bace)
CN103415521B (zh) 2011-03-09 2016-01-06 詹森药业有限公司 用作β分泌酶(BACE)抑制剂的3,4-二氢-吡咯并[1,2-a]吡嗪-1-基胺衍生物
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
KR20140084146A (ko) 2011-10-13 2014-07-04 노파르티스 아게 신규 옥사진 유도체 및 질환의 치료에서의 그의 용도
UA111749C2 (uk) 2011-12-05 2016-06-10 Янссен Фармацевтика Нв Похідні 6-дифторметил-5,6-дигідро-2h-[1,4]оксазин-3-аміну
WO2013083556A1 (en) * 2011-12-06 2013-06-13 Janssen Pharmaceutica Nv 5-(3-aminophenyl)-5-alkyl-5,6-dihydro-2h-[1,4]oxazin-3-amine derivatives
SG11201403956VA (en) * 2012-01-26 2014-10-30 Hoffmann La Roche Fluoromethyl-5,6-dihydro-4h-[1,3]oxazines
CN104870000A (zh) 2012-12-20 2015-08-26 默沙东公司 作为bace抑制剂的c5,c6氧杂环稠合的亚胺基噻嗪二氧化物化合物,组合物及其用途
ES2721073T3 (es) 2013-06-12 2019-07-26 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-6,7-dihidro[1,2,3]triazolo[1,5 a]pirazina como inhibidores de beta-secretasa (BACE)
MX368326B (es) 2013-06-12 2019-09-27 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-5,6-dihidroimidazo[1,5-a]pirazin-3(2h )-ona como inhibidores de beta-secretasa (bace).
CA2911690C (en) 2013-06-12 2021-08-24 Janssen Pharmaceutica Nv 4-amino-6-phenyl-5,6-dihydroimidazo[1,5-a]pyrazine derivatives as inhibitors of beta-secretase (bace)
US10106524B2 (en) 2014-12-18 2018-10-23 Janssen Pharmaceutica Nv 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2H-pyrrol-5-amine compound inhibitors of beta-secretase

Also Published As

Publication number Publication date
EP3233834B1 (en) 2019-11-13
US10106524B2 (en) 2018-10-23
ZA201704116B (en) 2019-12-18
KR20170095881A (ko) 2017-08-23
ES2768823T3 (es) 2020-06-23
EP3233834A1 (en) 2017-10-25
MX2017008083A (es) 2017-10-31
CN107108582B (zh) 2019-10-18
US20170362198A1 (en) 2017-12-21
EA031041B1 (ru) 2018-11-30
AU2015367594B2 (en) 2019-07-18
CA2967164A1 (en) 2016-06-23
JP2017538753A (ja) 2017-12-28
WO2016096979A1 (en) 2016-06-23
EA201791367A1 (ru) 2017-10-31
AU2015367594C1 (en) 2019-10-31
CN107108582A (zh) 2017-08-29
AU2015367594A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
IL321844A (en) Menin–MLL interaction inhibitors
IL259560A (en) Inhibitors of the menin-mll interaction
IL258180B (en) Heterocyclic compounds and their uses
PL3512850T3 (pl) Inhibitory interakcji menina-mll
ZA201704382B (en) 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of parg
ZA201702402B (en) Heteroaryl compounds as irak inhibitors and uses thereof
GB201514756D0 (en) Compound and method of use
IL251932B (en) Benzylpropargyl ether as nitrification inhibitors
ZA201704116B (en) 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase
SG11201708027XA (en) Compounds and their use as bace1 inhibitors
SMT201900582T1 (it) Nuovo composto e procedimento
SG10201911204WA (en) Autotaxin inhibitors and uses thereof
IL265139B (en) Dopamine-b-hydroxylase inhibitors
EP3197885A4 (en) Heterocyclic compounds and use thereof
GB201612860D0 (en) Inhibitors
IL258870A (en) Substituted indazole compounds as rorgammat inhibitors and uses thereof
SMT202000653T1 (it) Nuovi inibitori di callicreina 7
IL247921A0 (en) Glutaminase inhibitor compounds, preparations containing them and their uses
EP3240540A4 (en) Hdac1,2 inhibitors and methods of using the same
GB201614874D0 (en) New compounds and uses
GB201602572D0 (en) New compound and uses
GB201409466D0 (en) Urea compounds and their use as enzyme inhibitors
AU2014901768A0 (en) Heterocyclic compounds and use of same
GB201409661D0 (en) Novel compounds and their use as kinase inhibitors
GB201405532D0 (en) Novel compounds and their use as Kinase inhibitors